AKUR8
27.7.2021 09:02:06 CEST | Business Wire | Press release
Akur8 is pleased to announce its collaboration with Beesafe and Compensa, two entities of VIG Poland, to enhance their pricing process. With this new milestone, Akur8 continues to expand its European footprint, with 7 countries to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005010/en/
Specifically developed for insurers, Akur8’s solution boosts their pricing processes by automating risk and demand modeling, using transparent Artificial Intelligence proprietary technology. The core benefit for insurers is greater speed-to-accuracy, while maintaining full transparency and control on the models created.
VIG (Vienna Insurance Group) is one of the largest insurance groups in the world and one of the leading insurers in Austria and CEE countries. By collaborating with Akur8 for their motor insurance lines, Compensa will further accelerate their digital transformation, transforming the very core pricing process. Beesafe, a new, fully digital and direct entity created by VIG Poland, will be using Akur8 to launch their new product, leveraging the accelerated time-to-market benefits.
“We are very happy to support Beesafe and Compensa, part of VIG Poland, in taking a critical step towards insurance pricing sophistication and spurring digital transformation in their field. We are particularly humbled to accompany Beesafe in the launch of their fully digital journey, to help them bring their product to Polish consumers in a timely manner.”, says Samuel Falmagne, CEO at Akur8.
“It is great to be able to support VIG Poland in the launch of a new venture, whilst also reinforcing Akur8’s presence in Europe, Poland being our seventh European country of presence to date.”, says Brune de Linares, Chief of Sales at Akur8.
“Beesafe is a purely digital venture with a strong insurtech identity that we are extremely proud to be launching despite a very challenging context undermined by Covid. This is a strong testimony to the team’s commitment to continue to fuel digital transformation in our sector, sustained by collaborations with top-notch solutions that Akur8 epitomizes, for a highly strategic process that is pricing, all the more when launching a new product.”, says Rafał Mosionek, CEO at Beesafe and Executive Committee Member at Compensa, VIG Poland.
About Akur8
Akur8
is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
About Beesafe
Beesafe
is a digital venture with a strong insurtech identity, benefiting from a quite unique positioning within the CEE area. The digital start-up was established by VIG, the leading insurance group in Austria, Central and Eastern Europe, to provide a dynamic distribution company with a unique customer offering, and potential for expansion into other countries where VIG operates.
About Compensa
Part of the Vienna Insurance Group, Compensa has been operating on the Polish market for many years, constantly developing its offer, service standards and sales network to exceed the expectations of the growing number of customers.
About VIG
Vienna Insurance Group (VIG)
is a leading specialist insurance company in Austria and Central and Eastern Europe. About 50 companies in 30 countries belong to it. It is a company with a long tradition, having strong brands and attaching great importance to customer proximity. VIG bases its activity on the foundation of almost 200 years of experience in the insurance industry. The Vienna Insurance Group, with around 25,000 employees, is the undisputed leader in the group's key markets and thus has an excellent market position enabling it to take advantage of long-term growth opportunities in a region with 180 million people.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom